Tobramycin suppresses Nf-κB activation, reducing pro-inflammatory cytokines and controlling excessive inflammation in lung infections, thus helping prevent further lung damage in conditions like cystic fibrosis. (Sun et al., 2024; Nguyen et al., 2002). The gene discussed is NFKB1; the disease is cystic fibrosis.